{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:56:48Z","timestamp":1782223008916,"version":"3.54.5"},"reference-count":15,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    A man in his 20s presented with fever, night sweats and marked leucocytosis (94\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    \/L). Cervical lymph node biopsy confirmed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). The disease was refractory to brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone, SMILE and pralatrexate. Subsequently, single-agent gemcitabine (1000 mg\/m\u00b2 on days 1, 8 and 15) induced complete remission, unconfirmed (CRu), after two cycles, enabling reduced-intensity allogeneic haematopoietic stem-cell transplantation from an HLA one-locus-mismatched related donor in the host-versus-graft direction. The patient remains in remission 36 months post-transplant. Throughout the course, serial leucocyte-to-lymphocyte ratio (LLR) measurements appeared to parallel disease activity, with elevation during refractory disease and normalisation in remission. This case suggests that single-agent gemcitabine may provide a feasible low-toxicity bridge to transplantation in selected refractory PTCL-NOS and that serial LLR measurements may represent a simple adjunctive marker of disease dynamics.\n                  <\/jats:p>","DOI":"10.1136\/bcr-2025-268692","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:35:27Z","timestamp":1782221727000},"page":"e268692","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Single-agent gemcitabine enabling successful bridging to allogeneic haematopoietic stem-cell transplantation in refractory peripheral T-cell lymphoma, not otherwise specified"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2278-5193","authenticated-orcid":false,"given":"Tomoya","family":"Kitagawa","sequence":"first","affiliation":[{"name":"Hematology, Kansai Electric Power Hospital, Osaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Izumi","sequence":"additional","affiliation":[{"name":"Hematology, Kansai Electric Power Hospital, Osaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Io","sequence":"additional","affiliation":[{"name":"Hematology, Kansai Electric Power Hospital, Osaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026062306351209000_19.6.e268692.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2026062306351209000_19.6.e268692.2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"2026062306351209000_19.6.e268692.3","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026062306351209000_19.6.e268692.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"2026062306351209000_19.6.e268692.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"2026062306351209000_19.6.e268692.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"2026062306351209000_19.6.e268692.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508"},{"key":"2026062306351209000_19.6.e268692.8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00892-4"},{"key":"2026062306351209000_19.6.e268692.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"2026062306351209000_19.6.e268692.10","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous transplantation as consolidation. in PTCL: GELTAMO\/FIL study","volume":"107","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"Haematologica"},{"key":"2026062306351209000_19.6.e268692.11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.79"},{"key":"2026062306351209000_19.6.e268692.12","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2019.37.15_suppl.7503","article-title":"First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation\u2014Final results of the AATT study","volume":"37","author":"Shmitz","year":"2019","journal-title":"JCO"},{"key":"2026062306351209000_19.6.e268692.13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.annonc.2025.01.023","article-title":"Peripheral T- and natural killer-cell lymphomas: ESMO\u2013EHA Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"d\u2019Amore","year":"2025","journal-title":"Annals of Oncology"},{"key":"2026062306351209000_19.6.e268692.14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s44178-023-00062-9","article-title":"Identification of leukocyte-lymphocyte ratio as a novel prognostic factor in Peripheral T-cell lymphoma","volume":"2","author":"Gao","year":"2023","journal-title":"Holist Integ Oncol"},{"key":"2026062306351209000_19.6.e268692.15","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.739286"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-268692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:35:28Z","timestamp":1782221728000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-268692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,23]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bcr-2025-268692"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-268692","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}